Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

325.00DKK
10:59am EDT
Change (% chg)

kr.-10.00 (-2.99%)
Prev Close
kr.335.00
Open
kr.333.00
Day's High
kr.333.00
Day's Low
kr.322.00
Volume
210,253
Avg. Vol
314,674
52-wk High
kr.393.00
52-wk Low
kr.100.00

BAVA.CO

Chart for BAVA.CO

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.47
Market Cap(Mil.): kr.9,290.22
Shares Outstanding(Mil.): 27.73
Dividend: --
Yield (%): --

Financials

  BAVA.CO Industry Sector
P/E (TTM): 379.47 40.17 40.89
EPS (TTM): 0.88 -- --
ROI: 2.19 16.80 16.14
ROE: 2.33 17.30 16.96
Search Stocks

Bavarian Nordic gets first profit from sales to U.S. vaccine stockpile

COPENHAGEN, March 11 - Danish biotech company Bavarian Nordic said smallpox vaccine sales to the United States for its stockpile programme has led to its first full-year profit in five years, and added that it expects its Ebola vaccine to generate revenue this year.

11 Mar 2015

BRIEF-Bavarian Nordic FY EBIT down to DKK 17 million

* FY revenue 1.22 billion Danish crowns ($175.11 million) versus 1.21 billion crowns year ago

11 Mar 2015

Bristol's $1 billion Bavarian deal may signal cancer vaccine revival

LONDON - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic.

04 Mar 2015

Bristol's $1 bln Bavarian deal may signal cancer vaccine revival

LONDON, March 4 - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic .

04 Mar 2015

Bavarian Nordic shares leap on $1 billion Bristol-Myers deal

COPENHAGEN - Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful.

04 Mar 2015

UPDATE 2-Bavarian Nordic shares leap on $1 bln Bristol-Myers deal

COPENHAGEN, March 4 - Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful.

04 Mar 2015

Bavarian sees results of Phase III Prostvac trial by early 2017

COPENHAGEN - Bavarian Nordic expects the full results of its Phase III trials for prostate cancer drug Prostvac by early 2017, Chief Executive Paul Chaplin said after the Danish firm struck a $1 billion supply deal with Bristol-Myers Squibb.

04 Mar 2015

Bavarian sees results of Phase III Prostvac trial by early 2017

COPENHAGEN, March 4 - Bavarian Nordic expects the full results of its Phase III trials for prostate cancer drug Prostvac by early 2017, Chief Executive Paul Chaplin said after the Danish firm struck a $1 billion supply deal with Bristol-Myers Squibb.

04 Mar 2015

Bavarian Nordic shares leap on $1 bln Bristol-Myers deal

COPENHAGEN, March 4 - Shares in Bavarian Nordic leapt as much as 39 percent on Wednesday after the Danish biotech company announced a prostate cancer drug deal with Bristol-Myers Squibb that could be worth at least $1 billion.

04 Mar 2015

BRIEF-Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic for PROSTVAC

* Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer immunotherapy

04 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks